Sareum Holdings (SAR) RNS Announcements

Add to Alert list
Date Time Source Announcement
09 Feb 2006 07:00 AM
RNS
USD5m Idenix Collaboration
26 Jan 2006 07:00 AM
RNS
Collaboration with UCB
19 Jan 2006 07:00 AM
RNS
H.Lundbeck A/S Collaboration
17 Jan 2006 07:00 AM
RNS
Collaboration with Organon
12 Jan 2006 07:00 AM
RNS
Bcl-2 added to Crystal Bank
10 Jan 2006 07:00 AM
RNS
Collaborative Agreement
05 Jan 2006 07:00 AM
RNS
Trading Update
13 Dec 2005 07:00 AM
RNS
Collaborative Agreement
24 Nov 2005 07:00 AM
RNS
Crystal Bank Developments
09 Nov 2005 08:48 AM
RNS
Holding(s) in Company
07 Nov 2005 11:02 AM
RNS
Result of AGM
27 Oct 2005 07:00 AM
RNS
Collaboration with Schering
10 Oct 2005 12:59 PM
RNS
Annual Report and Accounts
22 Sep 2005 07:00 AM
RNS
Cancer Therapy Deal
19 Sep 2005 07:00 AM
RNS
Preliminary Results
01 Sep 2005 07:00 AM
RNS
Launch of Crystal Bank
10 Aug 2005 07:00 AM
RNS
Deal with Spanish Pharma
01 Aug 2005 09:30 AM
RNS
Holding(s) in Company
29 Jul 2005 03:32 PM
RNS
Holding(s) in Company
25 Jul 2005 07:00 AM
RNS
Major Drug Collaboration
30 Jun 2005 07:00 AM
RNS
Success Milestone
13 May 2005 07:00 AM
RNS
First UK Installation
25 Apr 2005 12:59 PM
RNS
Offer discussions terminated
11 Apr 2005 07:00 AM
RNS
Contract Extension
29 Mar 2005 07:00 AM
RNS
Interim Results
07 Mar 2005 12:01 PM
RNS
Rule 8 - Sareum Holdings plc
07 Mar 2005 07:00 AM
RNS
Rule 2.10 Announcement
04 Mar 2005 07:00 AM
RNS
Statement re speculation
15 Dec 2004 07:00 AM
RNS
Collaboration
06 Dec 2004 07:00 AM
RNS
New Cancer Collaboration
03 Dec 2004 04:14 PM
RNS
Shareholding
01 Dec 2004 07:00 AM
RNS
Drug Discovery Collaboration
29 Nov 2004 02:13 PM
RNS
Holding(s) in Company
22 Nov 2004 07:00 AM
RNS
Collaboration Agreement
15 Nov 2004 11:56 AM
RNS
Holding(s) in Company
09 Nov 2004 07:00 AM
RNS
Collaborative Agreement
26 Oct 2004 05:29 PM
RNS
Holding(s) in Company
11 Oct 2004 07:00 AM
RNS
First day of dealings on AIM

Sareum Holdings Plc (Sareum) is a clinical-stage drug discovery and development company that produces targeted small-molecule therapeutics for treating cancer and autoimmune diseases.

The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library (SKIL). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (checkpoint kinase 1), Aurora+FLT3 kinase, Autoimmune-TYK2/JAK1 kinases, and Cancer-TYK2/JAK1 kinases. Sareum's Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Cambridge, the UK.

SAR share price listed on AIM in 2004 under the ticker SAR.

UK 100

Latest directors dealings